Kiniksa Pharmaceuticals International, plc KNSA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's stock-based comp?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported stock-based comp of $10.06M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's stock-based comp changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's stock-based comp increased by 29.8% year-over-year, from $7.75M to $10.06M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's stock-based comp?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's stock-based comp has grown at a 10.1% compound annual growth rate (CAGR), from $25.17M to $37M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.